EFTA02361909

Extracted Text (OCR)

EFTA Disclosure

Text extracted via OCR from the original document. May contain errors from the scanning process.

From: Richard Kahn Sent: Thursday, August 13, 2015 9:03 PM To: jeffrey E. Subject: Avalanche Biotechnologies beats by $0.01, misses on revenue Aug 13 2015, 16:45 ET I About: Avalanche Biotechnologies (AAVL) <http://seekingalpha.com/symbol/AAVL> I By: Mohit Manghnani <http://seekingalpha.com/author/sa-editor-mohit-manghnani> , SA News Editor <http://seekingalpha.com/images/mail_icon.png> • $0.01. Revenue of $0.2M (+42.9% Y/Y) misses by $0.56M. * Shares -13.2%. Avalanche Biotechnologies (NASDAQ:AAVL <http://seekingalpha.com/symbol/aavl> ): Q2 EPS of -$0.38 beats by http://seekingalpha.com/pr/14409436-avalanche-biotechnologies-inc-reports-second-quarter-2015-financial-results- and-provides-update-on-avaminus-101-program Richard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York, NY 10022 tel 212-971-1306 fax 646-350-0954 cell 917-414-7584 1 EFTA_R1_01354253 EFTA02361909

Technical Artifacts (11)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

Faxfax 646-350-0954

Phone14409436

Phone212-971-1306

Phone2361909

Phone646-350-0954

Phone917-414-7584

URLhttp://seekingalpha.com/author/sa-editor-mohit-manghnani

URLhttp://seekingalpha.com/images/mail_icon.png

URLhttp://seekingalpha.com/pr/14409436-avalanche-biotechnologies-inc-reports-second-quarter-2015-financial-results

URLhttp://seekingalpha.com/symbol/AAVL

URLhttp://seekingalpha.com/symbol/aavl

Summary

Ask AI About This Document

Extracted Text (OCR)

Technical Artifacts (11)

Related Documents (6)

EFTA Document EFTA01765224

EFTA02328489

EFTA Document EFTA02125460

From: "Jeffrey E." <[email protected]>

EFTA02489202

EFTA02086739

Forum Discussions